2nd World ADC Awards Shortlist
-
Upload
world-adc -
Category
Health & Medicine
-
view
1.238 -
download
4
Transcript of 2nd World ADC Awards Shortlist
2nd World ADC Awards Shortlist Announced
2nd World ADC Awards Shortlist
AMG595 (Amgen) Glembatumumab vedotin (Celldex) Mirvetuximab soravtansine (ImmunoGen) Sacituzumab govitecan (Immunomedics) SGN-CD33A (Seattle Genetics)
2nd World ADC Awards Shortlist
nnAA (Sutro Biopharma) PBD (Spirogen) Probodies (CytomX) SMARTag (Catalent) THIOMAB (Genentech)
2nd World ADC Awards Shortlist
Baxter Biopharma Solutions BSP Pharmaceuticals Lonza Novasep Piramal
2nd World ADC Awards Shortlist
Abgenomics ADC Therapeutics Formation Biologics Kolltan Stemcentrx
2nd World ADC Awards Shortlist
Debaene et al. (Anal Chem, 2014) MS and IM-MS for ADC Characterization Dommerholt J et al. (Nat Commun, 2014) Highly accelerated inverse electron-
demand cycloaddition of electron-deficient azides with aliphatic cyclooctynes Ducry et al. (Bioconjugate Chem, 2010) Antibody-drug conjugates: linking
cytotoxic payloads to monoclonal antibodies Lyon et al. (Nature, 2014) Self-hydrolyzing maleimides improve the stability and
pharmacological properties of antibody-drug conjugates Shen et al. (MABS, 2014) Conjugation site modulates the in vivo stability and
therapeutic activity of antibody-drug conjugates
2nd World ADC Awards Shortlist
Floris van Delft (SynAffix) Hans Peter Gerber (Pfizer) Patrick van Berkel (ADC Therapeutics) Phil Howard (MedImmune/Spirogen) Xavier Despinoy (Piramal)
Judges
Jagath Junutula, VP, Cellerant Therapeutics Dr. Jagath Reddy Junutula joined Cellerant in April 2014 as a Vice President, Antibody Discovery & Development. Prior to joining Cellerant, Jagath was at Genentech for 13 years focusing on oncology drug discovery and development, including discovery and validation of targets for treatment of cancer; design, development and pre-clinical validation of antibody drug conjugates (ADCs); engineering next-generation ADCs; and development of bi-specific antibody/protein based cancer immunotherapeutic platforms for treatment of different types of cancers. He developed a novel THIOMAB technology platform to generate site-specific antibody-drug conjugates (ADCs) to improve the therapeutic utility of antibodies. This technology has widely been accepted as a new standard for the development of therapeutic ADCs. Jagath has authored 60 peer-reviewed publications/patents and has presented his work at numerous international conferences. Jagath serves as an editorial board member of leading antibody therapeutics journal, mAbs.
David Meininger, Executive Director, Merck Dr. David Meininger joined Merck in 2011 as Head of Protein Sciences. He served as a member of the Biologics Review & Licensing Committee, as champion of the Adimab collaboration, as co-champion of the Ambrx antibody-drug conjugate collaboration and played a strategic role on other Merck partnerships. In 2013, Dr. Meininger joined the new Merck Research Labs Business Development & Licensing organization. His BD&L responsibilities include evaluation and transaction of in- and out-licensing deals involving biologic assets from pre-clinical through phase II, support of the Merck Research Ventures Fund team and other BD activities. Prior to joining Merck, Dr. Meininger held positions with Amgen, Boehringer Ingelheim, Genentech, and Tularik. Dr. Meininger holds a Ph.D. in Chemistry from the University of California, San Diego, a M.B.A. in Technology Management from the University of Washington and a B.S. in Chemistry from the University of Florida.
Judges
Ho Cho, VP, Celgene Dr. Ho Sung Cho is VP, Biotherapeutics at Celgene. Dr. Cho is a Protein Medicinal Chemist with over 24 years of experience in recombinant protein expression, purification, modification, and analysis. Prior to joining industry, Dr. Cho worked on the structural genomics project at the Lawrence Berkeley National Labs. He received his Ph. D. in Chemistry from the University of California at Berkeley.
Key Dates: July 31st – Nominations Close & Awards Shortlist Announced August 3rd – Shortlisted Organizations/ Individuals Invited to Submit Winner’s Proposal August 28th – Proposal Deadline September 7th – Judging Process Begins September 14th – Ceremony Registration Opens October 9th – Deadline for Requesting Places at the Awards Ceremony October 21st – 2nd World ADC Awards Ceremony takes place
2014 Winners
Most Promising Drug Candidate Winner: IMGN289 (ImmunoGen) Runner up: Polatuzumab vedotin (Genentech)
Best Scientific Innovation Winner: PBDs (Spirogen) Runner up: None
Best Contract Service Provider Winner: Piramal Runner up: Lonza
2014 Winners
Best Team Winner: Lonza Bioconjugates Team Runner up: ImmunoGen Scientific Leadership Runner up: Peter Senter’s Chemistry Group
Long Standing Contribution to the Field Winner: Peter Senter, Seattle Genetics Collected by Jonathan Drachman Runner up: Ravi Chari
Individual Input to the Industry in 2013/2014 Winner: Chris Martin, Spirogen Runner up: John Lambert, ImmunoGen
The 2nd World ADC Awards will run on October 21st in San Diego, in conjunction with World ADC San Diego. Visit www.worldadc-usa.com for more information.
Request an invite to this year’s 2nd World ADC Awards
Places at the World ADC Awards ceremony are free but are allocated on a first-come first-served basis. To have the opportunity to request an invite, register your interest with us today.
Email us on: [email protected]